Many of these regulated genes are associated with various diseases, which explains why the molecular targets of approximately 13% of U.S. Food and Drug Administration (FDA) approved drugs target nuclear receptors.
Mnogi od tih regulisanih gena su povezani sa raznim bolestima, što objašnjava zašto su molekulske mete za aproksimativno 13% lekova odobrenih od strane američke Uprave za hranu i lekove (FDA) nuklearni receptori.